Repurposed Cancer Drugs Show Promise in Repairing Gut Barrier for Crohn’s Disease Treatment

A potential breakthrough in Crohn’s disease treatment is emerging from research that repurposes existing cancer medications to repair the gut barrier, a key factor in the chronic inflammatory condition. Scientists from the University of Houston, Baylor College of Medicine, and The University of Texas MD Anderson Cancer Center have identified a stress signal in epithelial cells that prevents the intestinal lining from healing in Crohn’s patients. By targeting this signal with low doses of two cancer drugs, the team aims to interrupt the inflammatory cycle and restore the gut barrier’s ability to repair itself.

Shifting Focus from Symptoms to Root Causes

Crohn’s disease affects approximately 1 million Americans, causing chronic inflammation in the digestive tract. Traditional treatments have primarily focused on managing symptoms with anti-inflammatory medications, but these approaches offer sustained remission for only about 20% of patients. The new research, published in Gastro Hep Advances, proposes a fundamental shift in strategy—addressing the underlying epithelial defects that drive both gut barrier dysfunction and immune system overactivity.

“The disease is driven by inherent defects in the epithelial lining, which also fuels the immune response,” the study authors explain. When the gut barrier is compromised, bacteria and toxins leak into surrounding tissues, triggering persistent inflammation and disease progression. Rather than suppressing inflammation alone, the team’s approach seeks to restore the gut’s natural regenerative capacity.

Repurposing Cancer Drugs for Gut Repair

The researchers are repurposing two existing cancer medications to target the stress signal in epithelial cells. By doing so, they aim to break the cycle of damage and inflammation, allowing the intestinal lining to heal. This strategy leverages decades of safety and efficacy data from oncology, potentially accelerating the timeline for clinical use in Crohn’s patients.

“Using low doses of these medications could bypass the decade-long wait for new drug development,” said University of Houston Professor Seema Khurana, a key contributor to the study. The team’s work builds on patient-derived “mini-organs,” or organoids, which demonstrate that the intestinal lining can be “taught” to repair itself when the stress signal is blocked.

From Anti-Inflammatory to Regenerative Medicine

Current Crohn’s treatments, such as biologics and immunosuppressants, primarily focus on dampening the immune response. While these therapies can reduce symptoms during flares, they do not address the root cause of the disease—the inability of the gut barrier to repair itself. The new approach represents a departure from this paradigm, prioritizing regeneration over suppression.

The study’s findings align with a growing body of research exploring regenerative medicine for inflammatory bowel diseases (IBD). Earlier this year, a separate team reported success in using probiotic-derived engineered outer membrane vesicles to promote intestinal barrier repair through antioxidant, anti-inflammatory, and microbiome-modulating effects. However, the repurposed cancer drugs offer a distinct advantage: they are already approved for other conditions, which could streamline their path to clinical trials for Crohn’s.

What’s Next for Patients and Clinicians

While the research is still in its early stages, the potential implications are significant. If successful, this approach could provide a new treatment option for the majority of Crohn’s patients who do not achieve long-term remission with current therapies. The team’s use of patient-derived organoids also opens doors for personalized medicine, allowing clinicians to test treatments on a patient’s own cells before administration.

However, experts caution that more research is needed to confirm the safety and efficacy of repurposed cancer drugs in Crohn’s patients. The long-term effects of these medications on gut health, immune function, and overall well-being remain unclear. The study’s focus on epithelial repair does not address other factors contributing to Crohn’s disease, such as genetic predisposition and environmental triggers.

For now, the findings offer a promising new direction in Crohn’s research—one that prioritizes healing over symptom management. As Professor Khurana noted, “This could change how we think about treating Crohn’s disease, moving from controlling inflammation to restoring the gut’s natural ability to repair itself.”

Broader Implications for Inflammatory Bowel Disease

The study’s regenerative approach could have applications beyond Crohn’s disease. Ulcerative colitis, another form of IBD, also involves gut barrier dysfunction and chronic inflammation. If the repurposed cancer drugs prove effective in Crohn’s, they may be explored for other conditions characterized by epithelial damage, such as celiac disease or certain gastrointestinal infections.

The research also highlights the potential of drug repurposing in accelerating medical breakthroughs. By leveraging existing medications with well-established safety profiles, scientists can reduce the time and cost associated with developing new treatments. This strategy is particularly valuable for chronic conditions like Crohn’s, where patients often face limited options and prolonged suffering.

As the scientific community awaits further developments, the study serves as a reminder of the importance of interdisciplinary collaboration. The partnership between the University of Houston, Baylor College of Medicine, and MD Anderson Cancer Center underscores how insights from oncology, immunology, and regenerative medicine can converge to address complex diseases. For the millions of people living with Crohn’s, this research offers a glimmer of hope—and a potential path toward lasting relief.